Navigation Links
Genta Receives Notice of Non-Compliance With NASDAQ Rule
Date:1/11/2008

Company to File Appeal

BERKELEY HEIGHTS, N.J., Jan. 11 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced today that the Company has received notice from the Listing Qualifications Staff of The NASDAQ Stock Market that, based upon the Company's non-compliance with the stockholders' equity requirement set forth in NASDAQ Marketplace Rule 4450(a)(3), the Company's common stock is subject to delisting from The NASDAQ Global Market unless the Company requests a hearing before a NASDAQ Listing Qualifications Panel. The Staff's letter follows prior correspondence from NASDAQ regarding the Company's stockholders' equity balance, which was previously disclosed in the Company's press release dated November 16, 2007.

The Company plans to timely request a hearing before the Panel, which will stay any delisting action until the Panel renders a decision subsequent to the hearing. The Company anticipates that the hearing will be scheduled within the next 45 days.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cance
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Genta Receives NASDAQ Non-Compliance Notice
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
10. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
11. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009).... 5 DSM Pharmaceutical Products to...iance with Galenix, Saint Jean D,Illac, France, wh...ufacturing partner for Galenix commercial products...laborate on business development opportunities co-...d on the strength of Galenix in drug product devel...
(Date:11/5/2009)...5 BioSpecifics Technolog...mpany developing first-in-class collagenase-based ...r the third quarter ended September 30, 2009. ,...this year, the FDA,s Arthritis Advisory Committee ...proval of XIAFLEX(TM) for the treatment of Dupuytr...
(Date:11/5/2009)... SpineSmith Partners has signed an...op a unique scaffold that mimics the structure of ...several commercial products by SpineSmith,s Resear...s the GenOsteo scaffold represents a significant a... ideal environment for the delivery of adult stem ...
(Date:11/4/2009)...his webinar, which will be presented on November 1...us flow chemistry processing, will deal with the a...arious meso and micro scale flow chemistry equipme... has been recognized with several prestigious priz...trahedron Prize. , Columb...
Breaking Biology Technology:DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 2Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 2Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 3
...imal patient discomfort, SPOKANE, Wash., Nov. 9 ...oday the launch of the ComforTen(TM) Multiple Skin...he device features ten,surgical steel 1.2mm lancet...table allergy testing. ComforTen is the only 10-te...the market. ComforTen is competitively,priced rela...
...ration (OTC Bulletin Board: CCYG) announced today ....S. patent (U.S. Patent No. 7,282,222) for its,uni...nd direct stem cells,to target organs in the body....licensed to CellCyte,from the US Department of Vet... enabling therapeutic products designed to allow m...
.... (Amex: PTN ) announced today financial results ...latin reported a net loss of $247,000, or $0.00,pe...eptember 30, 2007,compared to a net loss of $8.4 m...r the same period in 2006. Total revenues for the ..., compared to $4.9 million for the same,period in ...
Other Biology Technology:HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 2HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 3Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington 2Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington 3Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington 4Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007 2Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007 3Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007 4Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007 5Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007 6
(Date:11/5/2009)...ion of Biology Teachers (NABT) will recognize Leon... at Naugatuck Valley Community College (NVCC) in W...cation Award during the NABT annual professional d...09 in Denver, Colorado. , The Evolution Educatio...f Biological Sciences,(AIBS) and Biological Scien...
(Date:11/5/2009)... has been awarded a training grant in the amount o...der its Integrative Graduation Education and Resea...ERT grant to be awarded to Kent State. The grant, ...investment Act of 2009, runs through 2014. , The...ronment aquatic resource sensing (EARS). The purpo...
(Date:11/4/2009)...n natural science) , United States Using Less ... today than it did 35 years ago, despite a 30 perc... partly attributable to alternative cooling method...stems. According to the latest USGS water use repo...ates goes to cooling thermoelectric power plants. ...
Breaking Biology News(10 mins):Biologists, educators recognize excellence in evolution education 2Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7Hormone clue to root growth 9134 1Hormone clue to root growth 9134 2EnVivo to Share Results of its EVP 6124 Phase Ib IIa Trial at The International Conference on Alzheimers Disease 50909 1EnVivo to Share Results of its EVP 6124 Phase Ib IIa Trial at The International Conference on Alzheimers Disease 50909 2Johnson 26 Johnson to Host Analyst Conference Call on Second Quarter Results 50905 1
...niversity in St. Louis and their collaborators fro...es of rice varieties and have determined that the ... in various Asian locales. , Jason Londo, Washingt...ral candidate, and his adviser, Barbara A. Schaal,...essor of Biology in Arts & Sciences, ran genet...
...ost people and it triggers thoughts of their battl...ty of Alberta researcher has found an important sp...ark Graham, a PhD student from the Department of B...e first time the benefits of pollen on boreal lake...nent of plant fertilization but few think of its i...
...an researchers in the world have called for a new ...tive to help reduce and prevent amphibian declines...proportion that is continuing to get worse. In a p...nal Science, the scientists say that 32 percent of... nine ?perhaps as high as 122 ?have become extinct...
Other Biology News:Biologists find regions of rice domestication 2Major initiative proposed to address amphibian crisis 2Major initiative proposed to address amphibian crisis 3
Sheep Anti-Human Factor XIII Antibody, Horseradish Peroxidase Conjugated from CEDARLANE Laboratories Limited
Immunoblot Blocking Reagent from Upstate
Rabbit Anti-DAP12 Polyclonal Antibody, Unconjugated from Exalpha Biologicals, Inc.
Amido Black 10B, CI 20470 from Research Organics, Inc.
Biology Products: